For most cancers, if not all, angiogenesis is considered crucial for the progression of a localized tumor into an invasive cancer. Therapeutics targeting angiogenesis have been used successfully for the treatment of breast cancer, lung cancer, kidney cancer, and colon cancer. Recent reports, however, have provided evidence that clinical resistance to antiangiogenic agents can develop and that initial responses to these agents can lead to the development of more aggressive tumors. Early observations also indicate that lymphangiogenesis could promote tumor progression and pose a major challenge to the treatment of cancer with antiangiogenic therapy. The Journal of Oncology is, therefore, issuing an invitation to publish original research articles as well as review articles focusing on tumor vascularization and development of novel strategies targeting tumor angiogenesis and lymphangiogenesis.

Potential topics include but are not limited to:

• Mechanisms contributing to the initial angiogenic switch in tumors
• Influence of the tumor microenvironment on angiogenesis
• Pericytes and vessel maturation in tumor angiogenesis
• Molecular mechanisms of resistance to tumor antiangiogenic strategies
• Tumor lymphangiogenesis as a potential therapeutic target
• Role of lymphangiogenesis in tumor progression and resistance to antiangiogenic therapy
• Mechanisms contributing to the development of aggressive tumors failing antiangiogenic therapy
• Biological markers for predicting clinical response to antiangiogenic strategies
• Radiological markers of tumor response
• Mathematical models of the evolution of tumor vascularization
• Antiangiogenic and vascular disrupting agents